We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Impact of iMRI on the Extent of Resection in Patients With Newly Diagnosed Glioblastomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02379572
Recruitment Status : Completed
First Posted : March 5, 2015
Last Update Posted : October 22, 2021
Information provided by (Responsible Party):
University Hospital Tuebingen

Brief Summary:

Standard treatment of glioblastomas (GBMs) consists of microsurgical resection followed by concomitant chemoradiation. The extent of resection is one of the most important prognostic factors with significant influence on the survival of patients. State of the art technique to achieve the most radical resection possible in conventional surgery is fluorescence-guidance with 5-aminolevulinic acid (5-ALA). If available, intraoperative MRI (iMRI)-guided tumor resection enables an intraoperative resection control and subsequent continuation of surgery if contrast enhancing tumor remnants are found. Therefore a more radical resection and longer survival of patients might be possible. To date no comparison of these two leading technologies for GBM-surgery is available to identify the best surgical therapy of this fatal disease and to justify significant healthcare-economic differences between both technologies.

Goal of this study is to assess the value of iMRI guidance in the resection of GBMs in comparison to conventional 5-ALA microsurgery. Primary endpoint is the number of total resections (no residual contrast enhancement) in the postoperative MRI (T1+CM within 48 hours after surgery) in each group. Secondary endpoints are perioperative clinical data, progression free survival, patients' clinical condition and overall survival.

The study design was chosen to be a parallel-group approach to compare iMRI and 5-ALA centers (n=13) to exclude possible bias which might be found by randomizing patients within individual iMRI centers and to have surgeons with the most experience possible in use of each respective technology.

Condition or disease Intervention/treatment Phase
Glioblastoma Device: iMRI-guided surgery Drug: 5-ALA-guided surgery Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 315 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Impact of iMRI on the Extent of Resection in Patients With Newly Diagnosed Glioblastomas - A Prospective Multicenter Parallel Group Clinical Trial
Study Start Date : June 2015
Actual Primary Completion Date : June 2020
Actual Study Completion Date : July 1, 2021

Arm Intervention/treatment
Experimental: iMRI-guided surgery
Resection of Glioblastomas with iMRI-guidance
Device: iMRI-guided surgery
For iMRI-guided glioma resections the surgery can be paused and a direct intraoperative resection control is possible by performing an intraoperative MRI scan. If residual tumor is found, the resection might be continued.

Active Comparator: 5-ALA-guided surgery
Resection of Glioblastomas with 5-ALA-fluorescence-guidance
Drug: 5-ALA-guided surgery
For 5-ALA guided glioma resections patients have to drink 100ml of a solution with 5-Aminolevulinic acid 4-6 hours before surgery. Intraoperatively the light source of the surgical microscope can be switched to a certain wave length to enable fluorescence of the glioma cells, which helps resecting the tumor as radical as possible.

Primary Outcome Measures :
  1. Complete resections in the postoperative MRI (T1+/-CM) within 48 hours after surgery [ Time Frame: 48 hour ]
    Completeness of resection in the postoperative MRI within 48h after surgery. Blinded analysis by an independent radiologist.

Secondary Outcome Measures :
  1. Patients' clinical condition (KPS) [ Time Frame: preoperative (day before surgery), 1 week, 3Months, 6Months, 9Months, 12Months after surgery ]
    -KPS clinical scoring

  2. Patients' clinical condition (NIHSS) [ Time Frame: preoperative (day before surgery), 1 week, 3Months, 6Months, 9Months, 12Months after surgery ]
    -NIHSS stroke score

  3. Patients' clinical condition (QoL) [ Time Frame: preoperative (day before surgery), 1 week, 3Months, 6Months, 9Months, 12Months after surgery ]
    -quality of life (EORTC) questionnaire

  4. ICU and hospital stay after surgery [ Time Frame: Time of hospital stay (average 7days) ]
    -ICU and overall hospital stay after surgery

  5. Patients' adjuvant treatment [ Time Frame: 3Months, 6Months, 9Months, 12Months after surgery ]
    -adjuvant treatment each patient has received

  6. Recurrent tumor growth (RANO criteria) [ Time Frame: 3Months, 6Months, 9Months, 12Months after surgery ]
    -recurrent tumor growth (RANO criteria) according to local tumor boards and independent blinded analysis

  7. Follow-up imaging [ Time Frame: 3Months, 6Months, 9Months, 12Months after surgery ]
    -follow-up imaging 3, 6, 9, 12 months postoperative incl. independent blinded analysis

  8. Histology [ Time Frame: 1 week after surgery ]
    Histological analysis

  9. MGMT (O6-methylguanine-DNA-methyltransferase) analysis [ Time Frame: 1 week after surgery ]
    MGMT promoter analysis (Routine molecular diagnostics)

  10. IDH-1 (isocitrate dehydrogenase) analysis [ Time Frame: 1 week after surgery ]
    IDH-1 mutation analysis (Routine molecular diagnostics)

  11. Progression-free survival (PFS) [ Time Frame: Day of surgery - 6 months - 12 months ]

  12. Overall survival (OS) [ Time Frame: Day of surgery - Death of patient (Max. 10 years follow-up) ]
    OS of patients

Other Outcome Measures:
  1. Preoperative tumor localization and resectability concerning eloquent regions [ Time Frame: Blinded analysis of preoperative imaging (not older than 3 days prior to surgery) ]
    Independent blinded analysis of the preoperative imaging data by a blinded neurosurgeon with extensive experience in the resection of gliomas. Analysis will be done before the final evaluation of results. (Within 12 months)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. In MRI suspected primary singular untreated GBM
  2. Planned total resection of the tumor according to the surgeon
  3. Patient ≥18 years, ≤80 years
  4. Preoperative KPS ≥ 60%, American Society of Anesthesiologists (ASA) score 1 and 2
  5. Patients' informed consent

Exclusion Criteria:

  1. Tumors of the midline, basal ganglia, cerebellum, brain stem, eloquent areas
  2. Multifocal glioblastoma
  3. Substantial (>50%), non-contrast enhancing tumor areas suggesting low-grade glioma with malignant transformation
  4. Contraindications to MRI
  5. Inability to give consent because of language barrier or dysphasia
  6. Histological diagnosis other than Glioblastoma multiforme WHO °IV
  7. Increased risk of thrombosis (e.g. Factor V Leiden)
  8. Pregnancy or breast feeding
  9. Hypersensibility for 5-ALA oder porphyrins
  10. Acute or chronic Porphyria
  11. Renal insufficiency
  12. Hepatic insufficiency
  13. High likelihood of inability to receive adjuvant therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02379572

Layout table for location information
Department of Neurosurgery, Universitätsklinikum Bonn, Bonn, Germany
Bonn, Germany
Department of Neurosurgery, Universität zu Köln, Köln, Germany
Cologne, Germany
Städtisches Klinikum Dresden Friedrichstadt
Dresden, Germany
Department of Neurosurgery, Heinrich-Heine-Universität Düsseldorf, Düsseldorf
Düsseldorf, Germany
Department of Neurosurgery, Friedrich-Alexander-University Erlangen-Nürnberg
Erlangen, Germany
Department of Neurosurgery, Johann Wolfgang Goethe-University Frankfurt am Main
Frankfurt a.M., Germany
Department of Neurosurgery, Georg-August-Universität Göttingen, Göttingen,
Göttingen, Germany
Department of Neurosurgery, University of Ulm, Hospital Günzburg,
Günzburg, Germany
Asklepios Klinik Hamburg, Klinik für Neurochirurgie
Hamburg, Germany
International Neuroscience Institute Hannover, Hannover, Germany
Hannover, Germany
Department of Neurosurgery, Ruprecht-Karls-University Heidelberg
Heidelberg, Germany
Department of Neurosurgery, University of Schleswig-Holstein, Kiel, Germany
Kiel, Germany
Department of Neurosurgery, Westfälische Wilhelms-Universität Münster, Münster, Germany
Münster, Germany
Department of Neurosurgery, Eberhard Karls University, Tübingen,
Tübingen, Germany
Department of Neurosurgery, Julius-Maximilians-Universität Würzburg
Würzburg, Germany
Sponsors and Collaborators
University Hospital Tuebingen
Layout table for investigator information
Principal Investigator: Constantin Roder, Dr. University Hospital Tuebingen, Department of Neurosurgery
Layout table for additonal information
Responsible Party: University Hospital Tuebingen
ClinicalTrials.gov Identifier: NCT02379572    
Other Study ID Numbers: Nch1
First Posted: March 5, 2015    Key Record Dates
Last Update Posted: October 22, 2021
Last Verified: July 2020
Keywords provided by University Hospital Tuebingen:
Intraoperative MRI
Extent of resection
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue